T-Cell-Specific Gfi-1 Knockout Mouse
New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications
Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF)
Mutants Having a Deficit of Functional Steroid Hormone Receptors
A Tet-Regulated Mouse Model for Cataract
Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions
Transgenic mouse models expressing human HLA-B57:01 and HLA-B15:02 molecules have emerged as invaluable tools for unraveling the intricacies of immune responses and hypersensitivity reactions. The major histocompatibility complex (MHC) encoded proteins play a pivotal role in the immune system by presenting peptide fragments to T lymphocytes, and HLA-B57:01 has been associated with severe hypersensitivity reactions triggered by abacavir, a widely used anti-retroviral drug.
A Mouse Model for Human Osteoarthritis
DLX3 Knockout Mice for the Study Mouse Models of Tooth, Hair, and Epidermal Defects
This technology includes K14creDLX3 conditional knockout (cKO) mice which will be used to study ectodermal dysplasia disorders such as Amelogenesis Imperfecta, and to study molecular mechanisms of DLX3 regulation in skin and ectodermal appendages. DLX3 is expressed in the epidermis, hair matrix cells in the hair follicle and in the mesenchymal and epithelial compartment of the tooth during embryonic development. To determine the transcriptional network dependent on DLX3-function, we will generate and analyze an epithelial-specific conditional knockout of DLX3.
Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus
There are five known Ebolavirus species: Ebola virus (Zaire ebolavirus); Sudan virus (Sudan ebolavirus or SUDV); Taï Forest virus (Taï Forest ebolavirus, formerly Cote d'Ivoire ebolavirus); Bundibugyo virus (Bundibugyo ebolavirus); and Reston virus (Reston ebolavirus). Last year an ebolavirus outbreak resulted in 164 cases and 55 deaths. While there is an FDA-approved Ebola virus vaccine authorized for use against Ebola virus infections, ERVEBO, this vaccine is not effective against SUDV due to the significant variation between Ebola virus and SUDV.